drug_type
RELEVANT_DRUG
intervention_type
Biological (CAR T-cell therapy)
drug_description
An autologous chimeric antigen receptor (CAR) T-cell therapy targeting Claudin 18.2 (CLDN18.2). Patient T cells are engineered to express a CAR that binds CLDN18.2 on tumor cells, triggering T-cell activation, cytokine release, and perforin/granzyme-mediated cytotoxicity to lyse CLDN18.2-positive cancer cells.
nci_thesaurus_concept_id
C192206
nci_thesaurus_preferred_term
Autologous Anti-Claudin18.2 CAR T-cells LB1908
nci_thesaurus_definition
A preparation of autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18), with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-CLDN18.2 CAR T-cells LB1908 specifically recognize and induce selective toxicity in CLDN18.2-expressing tumor cells. CLDN18.2, a tight junction protein, is expressed on a variety of tumor cells, but its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Immunotherapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered to express a CLDN18.2-specific chimeric antigen receptor (CAR). Binding to CLDN18.2 on tumor cells activates the T cells, leading to cytokine release and perforin/granzyme-mediated cytotoxic killing of CLDN18.2-positive cancer cells.
drug_name
LB1908
nct_id_drug_ref
NCT05539430